We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates
Read MoreHide Full Article
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) posted first-quarter 2020 adjusted earnings per share (EPS) of $1.70, which surpassed the Zacks Consensus Estimate by 22.3%. The figure however declined 9.1% year over year.
On a reported basis, the company registered loss of $2.46 per share, a significant decline from the year-ago earnings of $1.20 per share.
A significant year-over-year decline in the company’s first-quarter revenuesand operating margin, negatively impacted by the coronavirus outbreak, resulted in poor earnings performance of Zimmer Biomet.
Revenue Details
First-quarter net sales of $1.78 billion decreased 9.7% (down 8.9% at constant exchange rate or CER) year over year. The figure also missed the Zacks Consensus Estimate by 0.3%. The company noted that the coronavirus pandemic resulted in the deferral of elective procedures during the quarter.
Zimmer Biomet Holdings Inc Price, Consensus and EPS Surprise
During the first quarter, sales generated in the Americas totaled $1.10 billion (down 7.7% year over year at CER) while the same in EMEA (Europe, the Middle East and Africa) grossed $398 million (down 11.7% year over year at CER). Asia-Pacific registered 9.5% decline at CER to $285 million.
Segments
Sales in the Knees unit declined 8.3% year over year at CER to $630 million. Hips recorded a 9.7% drop at CER to $433 million. Revenues in the S.E.T. (Sports Medicine, Extremities and Trauma) unit declined 6.5% year over year to $333 million.
Among other segments, Dental, Spine & CMFT(Craniomaxillofacial and Thoracic) dropped 11.8% at CER to $252 million. Other revenues were down 11% to $136 million.
Margins
Gross margin after excluding intangible asset amortization came in at 72.7%, reflecting an expansion of 71 basis points (bps) in the first quarter. Selling, general and administrative expenses increased 4.1% to $828.9 million. Research and development expenses declined 3.2% to $98.4 million. Adjusted operating margin contracted 582 bps to 20.1% during the quarter.
Cash Position
Zimmer Biomet exited the first quarter with cash and cash equivalents of $2.43 billion compared with $617.9 million at 2019 end. Long-term debt at the end of the quarter totaled $7.72 billion, reflecting a rise from $6.72 billion at the end of 2019.
At the end of the first quarter, net cash provided by operating activities was $450.9 million compared with $283.6 million in the year-ago period.
2020 Guidance
Zimmer Biomet expects the decline in elective procedure volumes to intensify in the second quarter of 2020. Given the uncertainty related to the scope and duration of the pandemic and its ongoing impact on the deferral of elective procedures, the company is currently unable to gauge the expected impact on its overall all business in 2020. Accordingly, it did not provide any update on its full-year guidance.
Our Take
Zimmer Biomet ended the first quarter on a dismal note with disappointing sales performances across all operating segments and geographies. The company noted that first-quarter performance was negatively impacted by COVID-19, which reached a pandemic level in March and resulted in a significant and sudden decline in elective procedure volumes across all regions. However, Zimmer Biomet expects its strong fundamentals and capital structure to position it well to overcome the ongoing challenges. However, its expectation of a further decline in elective procedure volumes in the second quarter raises concern.
Zacks Rank and Stocks to Consider
Zimmer Biomet currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria carries a Zacks Rank #2 (Buy) at present. It reported third-quarter fiscal 2020 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million outpaced the consensus estimate by 14.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly currently sports a Zacks Rank #1. It delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) posted first-quarter 2020 adjusted earnings per share (EPS) of $1.70, which surpassed the Zacks Consensus Estimate by 22.3%. The figure however declined 9.1% year over year.
On a reported basis, the company registered loss of $2.46 per share, a significant decline from the year-ago earnings of $1.20 per share.
A significant year-over-year decline in the company’s first-quarter revenuesand operating margin, negatively impacted by the coronavirus outbreak, resulted in poor earnings performance of Zimmer Biomet.
Revenue Details
First-quarter net sales of $1.78 billion decreased 9.7% (down 8.9% at constant exchange rate or CER) year over year. The figure also missed the Zacks Consensus Estimate by 0.3%. The company noted that the coronavirus pandemic resulted in the deferral of elective procedures during the quarter.
Zimmer Biomet Holdings Inc Price, Consensus and EPS Surprise
Zimmer Biomet Holdings Inc price-consensus-eps-surprise-chart | Zimmer Biomet Holdings Inc Quote
During the first quarter, sales generated in the Americas totaled $1.10 billion (down 7.7% year over year at CER) while the same in EMEA (Europe, the Middle East and Africa) grossed $398 million (down 11.7% year over year at CER). Asia-Pacific registered 9.5% decline at CER to $285 million.
Segments
Sales in the Knees unit declined 8.3% year over year at CER to $630 million. Hips recorded a 9.7% drop at CER to $433 million. Revenues in the S.E.T. (Sports Medicine, Extremities and Trauma) unit declined 6.5% year over year to $333 million.
Among other segments, Dental, Spine & CMFT(Craniomaxillofacial and Thoracic) dropped 11.8% at CER to $252 million. Other revenues were down 11% to $136 million.
Margins
Gross margin after excluding intangible asset amortization came in at 72.7%, reflecting an expansion of 71 basis points (bps) in the first quarter. Selling, general and administrative expenses increased 4.1% to $828.9 million. Research and development expenses declined 3.2% to $98.4 million. Adjusted operating margin contracted 582 bps to 20.1% during the quarter.
Cash Position
Zimmer Biomet exited the first quarter with cash and cash equivalents of $2.43 billion compared with $617.9 million at 2019 end. Long-term debt at the end of the quarter totaled $7.72 billion, reflecting a rise from $6.72 billion at the end of 2019.
At the end of the first quarter, net cash provided by operating activities was $450.9 million compared with $283.6 million in the year-ago period.
2020 Guidance
Zimmer Biomet expects the decline in elective procedure volumes to intensify in the second quarter of 2020. Given the uncertainty related to the scope and duration of the pandemic and its ongoing impact on the deferral of elective procedures, the company is currently unable to gauge the expected impact on its overall all business in 2020. Accordingly, it did not provide any update on its full-year guidance.
Our Take
Zimmer Biomet ended the first quarter on a dismal note with disappointing sales performances across all operating segments and geographies. The company noted that first-quarter performance was negatively impacted by COVID-19, which reached a pandemic level in March and resulted in a significant and sudden decline in elective procedure volumes across all regions. However, Zimmer Biomet expects its strong fundamentals and capital structure to position it well to overcome the ongoing challenges. However, its expectation of a further decline in elective procedure volumes in the second quarter raises concern.
Zacks Rank and Stocks to Consider
Zimmer Biomet currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria carries a Zacks Rank #2 (Buy) at present. It reported third-quarter fiscal 2020 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million outpaced the consensus estimate by 14.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly currently sports a Zacks Rank #1. It delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>